GlassScriptPhysician profile
Crystal M Webb
NPI 1861935918
$4,179.32
in general payments reported to CMS, 2019-2025
28 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $520 · 2022: $699 · 2023: $760 · 2024: $1,114 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,948 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.22 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,276.79 | 2021-2025 | Ozempic, Rybelsus, Sogroya |
| Corcept Therapeutics | $855.32 | 2023-2025 | Korlym |
| Antares Pharma, INC. | $255.97 | 2021-2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $212.49 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $204.59 | 2022-2023 | Farxiga |
| Lilly USA, LLC | $185.46 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Tandem Diabetes Care, INC. | $164.64 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $116.09 | 2024-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $100.73 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $89.87 | 2024-2025 | Strensiq |
| Tolmar, INC. | $80.75 | 2024-2025 | Jatenzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.59 | 2024-2025 | Jardiance |
| Abbott Laboratories | $65.42 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $54.34 | 2024-2025 | |
| Astellas Pharma US INC | $50.95 | 2024-2025 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $50.28 | 2025 | |
| Insulet Corporation | $48.91 | 2021-2022 | |
| Halozyme INC | $47.45 | 2023 | |
| Beta Bionics, INC. | $40.20 | 2024 | Ilet Bionic Pancreas |
| Amneal Pharmaceuticals LLC | $38.54 | 2023 | Unithroid |
| Sequel Med Tech, LLC | $33.68 | 2025 | Twiist |
| Ibsa Pharma INC. | $30.85 | 2021-2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $27.21 | 2022 | |
| Verity Pharmaceuticals INC. | $18.66 | 2024 | Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2025 | |
| Siemens Medical Solutions USA, INC. | $17.30 | 2024 | Atellica Im 1300 Analyzer, Atellica Ch 930 Analyzer |
| Lifescan, INC. | $13.59 | 2023 | |
| Currax Pharmaceuticals LLC | $13.30 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.